CSIMarket Company Name, Ticker, Competitors, else..
Taysha Gene Therapies Inc   (NASDAQ: TSHA)
Other Ticker:  
 


 

Taysha Gene Therapies Inc

TSHA's Financial Statements and Analysis



Taysha Gene Therapies Inc narrowed third quarter of 2025 net loss per share of $-0.09 compare to net loss per share of $-0.10 recorded in the same quarter a year ago a decrease compare to $-0.09 realized in previous quarter.


third quarter of 2025
Earnings Per Share Revenues
$ -0.09 $  0 Mill
$+0.01     $-2M    



Taysha Gene Therapies Inc 's Revenue fell by 0 % in third quarter of 2025 (Sep 30 2025) year on year, to $0 million and declined by sequentially.


Taysha Gene Therapies Inc is

More on TSHA's Income Statement



Taysha Gene Therapies Inc in the third quarter of 2025 recorded net loss of $-32.733 million, an increase from net loss of $-25.524 million in III. Quarter a year ago.

Sequentially net loss advanced

More on TSHA's Growth

Taysha Gene Therapies Inc Inventories
In Sep 30 2025 company's net cash and cash equivalents decreased by $-15 million, capital expenditures fell by -0.035208.57%, to $0 millions compare to same quarter a year ago

More on TSHA's Cash flow Statement


Taysha Gene Therapies Inc does not pay out common stock dividend.

In trailing twelve-month period Taysha Gene Therapies Inc payed $ -0.24 cash per share, on a free-cash flow basis .

Book value fell by -25.74 % sequentially to $0.62 per share, -70.28% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.62 per share from $ 0.83.

Company issued 55.32 million shares or 18.56 % in Sep 30 2025.


• More on TSHA's Dividends

 Market Capitalization (Millions) 1,459
 Shares Outstanding (Millions) 353
 Total Debt (Millions $) 51
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -100
 Cash Flow (TTM) (Millions $) 140
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 80




Taysha Gene Therapies Inc does not pay out common stock dividend.

In trailing twelve-month period Taysha Gene Therapies Inc had negative $ -0.24 cash flow per share, on a free-cash flow basis .

Book value fell by -25.74 % sequentially to $0.62 per share, -70.28% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.62 per share from $ 0.83.

Company issued 55.32 million shares or 18.56 % in Sep 30 2025.


• More on TSHA's Balance Sheets

 Market Capitalization (Millions) 1,459
 Shares Outstanding (Millions) 353
 Total Debt (Millions $) 51
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -100
 Cash Flow (TTM) (Millions $) 140
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 80
   


  News about Taysha Gene Therapies Inc Earnings

Taysha Gene Therapies Inc Sets New Revenue Record of $4.746 Million, Signaling Bright Future Ahead

Exciting Times Ahead for Taysha Gene Therapies Inc: Record Revenue and Promising Outlook
The stock market is always abuzz with news, and today we have some thrilling updates on Taysha Gene Therapies Inc., a prominent name in the field of gene therapies. In their recent disclosure, the company announced an impressive revenue of $4.746 million during the third quarter of the 2023 earnings season. This remarkable achievement reflects the company's remarkable progress and increasing market presence.
Taysha Gene Therapies Inc has been working tirelessly to push the boundaries of gene therapy and make breakthroughs in treating various genetic diseases. While their revenue figures are indeed impressive, it ...

Taysha Gene Therapies Inc Experiences Significant Growth in Share Prices While Reporting $2.395 Million Revenue in Q2 2023

Taysha Gene Therapies Inc, a leading gene therapy company, has witnessed a significant increase in its share prices recently. Over the last five trading days, the company's shares recorded a solid gain of 8.55%. Furthermore, over the past 30 days, the shares have seen a substantial increase of 11.91%. Despite these positive trends, it is worth noting that the shares are currently trading on the NASDAQ at a significant discount of 51.6% below its 52-week average.
One factor that may have contributed to the recent uptick in share prices is Taysha's financial performance in the period ending June 30, 2023. The company reported revenue of $2.395 million during this period, indicating a positive financial tra...

Despite Unexpected Net Loss, Taysha Gene Therapies Inc. Makes Strides Toward Success in Q1 2023

The latest financial report from Taysha Gene Therapies Inc (Taysha), a reputable Biotechnology and Pharmaceuticals company, has revealed a promising start to the first quarter of 2023 despite an unexpected net loss. The company reported $4.706 million in revenue in the first quarter of this year, and this figure marks a significant improvement compared to the same period in the previous year.
Although Taysha experienced net losses of $-17.622 million during the first quarter of 2023, the figure represents a massive improvement compared to a deficit of $-50.111 million in the same quarter of 2022. This unexpected loss may have been caused by ongoing investments and the costs associated with clinical trial...


Date modified: 2025-11-11T16:04:40+00:00




Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2025 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.